Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133179 | 0.88 | MEN1 (0.59) | NR3C1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL6293242 | 0.88 | NR3C1 (0.74) | NR3C1KMT2A | |
| SCHEMBL5961453 | 0.87 | KMT2A (0.57) | NR3C1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20418812 | 0.83 | NR3C1 (0.62) | NR3C1KMT2A | |
| SCHEMBL20418859 | 0.79 | KMT2A (0.66) | NR3C1KMT2A | |
| SCHEMBL20418851 | 0.79 | NR3C1 (0.66) | NR3C1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6290087 | 0.78 | NR3C1 (0.61) | NR3C1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4339575 | 0.78 | PDE4B (0.61) | NR3C1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20418829 | 0.77 | NR3C1 (0.64) | NR3C1KMT2A | |
| SCHEMBL20418840 | 0.77 | NR3C1 (0.68) | NR3C1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | NR3C1 673/4885KMT2A 4525/4885MEN1 2137/4885 |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | NR3C1 673/4885KMT2A 4525/4885MEN1 2137/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | NR3C1 1614/4885KMT2A 2063/4885MEN1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.